SimInhale COST action

On line with it’s research activity in the field of antibiotics aerosol for the treatment of lung infections, Inserm U1070 participates to the recently launched SimInhale COST action.

Simulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines (SimInhale)

Descriptions are provided by the Actions directly via e-COST.

As a result of the culmination of several scientific and technological developments, we are on the verge of technological breakthroughs in the field of inhaled medicines that will revolutionize the treatment of many acute or chronic respiratory and systemic illnesses. However, knowledge in the field is vertically fragmented and compartmentalized in disciplines. As a result, current developments are not necessarily synergistic and supportive of each other. The prospect of patient-tailored inhaled medicines necessitates a much closer coordination of research and development activities. Simlnhale aims to create a pan-European network of experts in order to: i) advance particle designs for improved deposition and interaction with lung tissue, ii) promote realistic computer simulations of particle aerosolization, delivery and deposition, iii) promote patient-tailored inhaled medicines, iv) promote integration of device and formulation design, and v) promote critical assessment of toxicity issues and related risks. Making a new generation of advanced inhaled pharmaceuticals available to patients in a shorter period of time will have enormous social benefits.





Menu principal

Haut de page